PMID- 21223721
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20181201
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 31
IP  - 10
DP  - 2010 Oct
TI  - [Study on clonal evolution of monosomy 7 in patients with aplastic anemia by 
      interphase- fluorescence in situ hybridization].
PG  - 688-92
AB  - OBJECTIVE: To explore the clonal evolution of monosomy 7 in patients with 
      aplastic anemia (AA). METHODS: Monosomy 7 (-7) in 81 AA patients with normal 
      karyotype at diagnosis and 46 AA treated with immunosuppressive therapy (IST) and 
      more than 6 months of recombinant human granulocyte colony-stimulating factor 
      (rhuG-CSF) were detected by interphase- fluorescence in situ hybridization (FISH) 
      retrospectively. RESULTS: There were 5.4% - 7.6% of -7 cells in 11 (13.6%) of 81 
      patients at diagnosis, the survival and response rate to IST in -7 positive 
      patients did not differ significantly from that in -7 negative patients (P = 
      0.481, 0.865); -7 cells disappeared after IST in all of the 11 patients including 
      5 received long-term rhuG-CSF therapy, and none of them evolved to 
      myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) at a median follow-up 
      of 44 months. Serial assessments of -7 clones were performed in 46 patients, none 
      of whom detected -7 clones 3-6 months after IST, but -7 recurrence in 5 patients 
      12 - 15 months after IST. At a median follow-up of 48 months, FISH identified 6 
      patients with -7 clones while the conventional cytogenetic analysis (CCA) 
      recognized in 5. Moreover, the first demonstration of -7 by FISH was 3 - 18 
      months earlier than that by CCA. All of the 6 patients with FISH detected -7 
      evolved to MDS/AML with -7 and four of them were retrospectively analysed for in 
      samples at -7 diagnosis of AA, but none of them was positive. CONCLUSIONS: 
      Monosomy 7 exists in a part of AA patients, but the preexisting -7 cells seems 
      neither associated with fatality nor evolvation to MDS/AML. rhuG-CSF might 
      facilitate the expansion of -7 clones; It is necessary to monitor -7 in AA, 
      especially when received long-term rhuG-CSF therapy.
FAU - Li, Ying-Mei
AU  - Li YM
AD  - Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, 
      China.
FAU - Liu, Xu-Ping
AU  - Liu XP
FAU - Li, Cheng-Wen
AU  - Li CW
FAU - Xu, Fang-Yun
AU  - Xu FY
FAU - Gong, Jin-Ying
AU  - Gong JY
FAU - Yu, Cheng-Long
AU  - Yu CL
FAU - Wang, Jian-Xiang
AU  - Wang JX
FAU - Zheng, Yi-Zhou
AU  - Zheng YZ
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
SB  - IM
MH  - Anemia, Aplastic/therapy
MH  - *Clonal Evolution
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Monosomy
MH  - Myelodysplastic Syndromes
EDAT- 2011/01/13 06:00
MHDA- 2016/04/24 06:00
CRDT- 2011/01/13 06:00
PHST- 2011/01/13 06:00 [entrez]
PHST- 2011/01/13 06:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2010 Oct;31(10):688-92.